Review Article
Open Access
Issue
Published:
28 February 2021
Open Access
Issue
Published:
28 February 2021
Tumor-associated macrophages as treatment targets in glioma
Wenbin Li
(
)
(
)
Cite this article:
Peng Y, Chen F, Li S, et al.
Tumor-associated macrophages as treatment targets in glioma.
Brain Science Advances,
2020, 6(4): 306-323.
https://doi.org/10.26599/BSA.2020.9050015
Download citation
748
Views
37
Downloads
Citations
10
Crossref
N/A
WoS
N/A
Scopus
N/A
CSCD
Gliomas, the most common primary tumors in the central nervous system (CNS), can be categorized into 4 grades according to the World Health Organization. The most malignant glioma type is grade Ⅳ, also named glioblastoma multiforme (GBM). However, the standard treatment of concurrent temozolomide (TMZ) chemotherapy and radiotherapy after maximum resection does not improve overall survival in patients with GBM. Targeting components of the CNS microenvironment represents a new strategy for improving the efficacy of glioma treatment. Most recent studies focused on T cells. However, there is a growing body of evidence that tumor-associated macrophages (TAMs) play an important role in tumor progression and can be regulated by a wide array of cytokines or chemokines. New TAM-associated immunotherapies may improve clinical outcomes by blocking tumor progression and prolonging survival. However, understanding the exact roles and possible mechanisms of TAMs in the tumor environment is necessary for developing this promising therapeutic target and identifying potential diagnostic markers for improved prognosis. This review summarizes the possible interactions between TAMs and glioma progression and discusses the potential therapeutic directions for TAM-associated immunotherapies.
menu
Abstract
Full text
Outline
About this article
Tumor-associated macrophages as treatment targets in glioma
Wenbin Li
(
)
(
)
Abstract
Gliomas, the most common primary tumors in the central nervous system (CNS), can be categorized into 4 grades according to the World Health Organization. The most malignant glioma type is grade Ⅳ, also named glioblastoma multiforme (GBM). However, the standard treatment of concurrent temozolomide (TMZ) chemotherapy and radiotherapy after maximum resection does not improve overall survival in patients with GBM. Targeting components of the CNS microenvironment represents a new strategy for improving the efficacy of glioma treatment. Most recent studies focused on T cells. However, there is a growing body of evidence that tumor-associated macrophages (TAMs) play an important role in tumor progression and can be regulated by a wide array of cytokines or chemokines. New TAM-associated immunotherapies may improve clinical outcomes by blocking tumor progression and prolonging survival. However, understanding the exact roles and possible mechanisms of TAMs in the tumor environment is necessary for developing this promising therapeutic target and identifying potential diagnostic markers for improved prognosis. This review summarizes the possible interactions between TAMs and glioma progression and discusses the potential therapeutic directions for TAM-associated immunotherapies.
Keywords:
tumor-associated macrophages, tumor progression, immunotherapy
References(117)
[1]
N Kamran, MS Alghamri, FJ Nunez, et al. Current state and future prospects of immunotherapy for glioma. Immunotherapy. 2018, 10(4): 317-339.
[2]
D Matias, J Balça-Silva, G Da Graça, et al. Microglia/astrocytes-glioblastoma crosstalk: Crucial molecular mechanisms and microenvironmental factors. Front Cell Neurosci. 2018, 12: 235.
[3]
T Miyazaki, E Ishikawa, M Matsuda, et al. Infiltration of CD163-positive macrophages in glioma tissues after treatment with anti-PD-L1 antibody and role of PI3Kγ inhibitor as a combination therapy with anti-PD-L1 antibody in in vivo model using temozolomide-resistant murine glioma-initiating cells. Brain Tumor Pathol. 2020, 37(2): 41-49.
[4]
HQ Wang, LY Zhang, IY Zhang, et al. S100B promotes glioma growth through chemoattraction of myeloid-derived macrophages. Clin Cancer Res. 2013, 19(14): 3764-3775.
[5]
T Muliaditan, J Caron, M Okesola, et al. Macrophages are exploited from an innate wound healing response to facilitate cancer metastasis. Nat Commun. 2018, 9(1): 2951.
[6]
A Mantovani, F Marchesi, A Malesci, et al. Tumour- associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017, 14(7): 399-416.
[7]
H You, S Baluszek, B Kaminska. Supportive roles of brain macrophages in CNS metastases and assessment of new approaches targeting their functions. Theranostics. 2020, 10(7): 2949-2964.
[8]
AL Hudson, NR Parker, P Khong, et al. Glioblastoma recurrence correlates with increased APE1 and polarization toward an immuno-suppressive microenvironment. Front Oncol. 2018, 8: 314.
[9]
P Domingues, M González-Tablas, Á Otero, et al. Tumor infiltrating immune cells in gliomas and meningiomas. Brain Behav Immun. 2016, 53: 1-15.
[10]
LJM Perus, LA Walsh. Microenvironmental heterogeneity in brain malignancies. Front Immunol. 2019, 10: 2294.
[11]
JW Zhou, ZW Tang, SY Gao, et al. Tumor-associated macrophages: Recent insights and therapies. Front Oncol. 2020, 10: 188.
[12]
C Morrison. Immuno-oncologists eye up macrophage targets. Nat Rev Drug Discov. 2016, 15(6): 373-374.
[13]
PF Zhao, YH Wang, XJ Kang, et al. Dual-targeting biomimetic delivery for anti-glioma activity via remodeling the tumor microenvironment and directing macrophage-mediated immunotherapy. Chem Sci. 2018, 9(10): 2674-2689.
[14]
F Balkwill, A Mantovani. Inflammation and cancer: Back to Virchow? Lancet. 2001, 357(9255): 539-545.
[15]
D Hambardzumyan, DH Gutmann, H Kettenmann. The role of microglia and macrophages in glioma maintenance and progression. Nat Neurosci. 2016, 19(1): 20-27.
[16]
S Khan, S Mittal, K Mcgee, et al. Role of neutrophils and myeloid-derived suppressor cells in glioma progression and treatment resistance. Int J Mol Sci. 2020, 21(6): 1954.
[17]
E Gomez Perdiguero, K Klapproth, C Schulz, et al. Tissue-resident macrophages originate from yolk- sac-derived erythro-myeloid progenitors. Nature. 2015, 518(7540): 547-551.
[18]
F Alliot, I Godin, B Pessac. Microglia derive from progenitors, originating from the yolk sac, and which proliferate in the brain. Brain Res Dev Brain Res. 1999, 117(2): 145-152.
[19]
L Sevenich. Brain-resident microglia and blood-borne macrophages orchestrate central nervous system inflammation in neurodegenerative disorders and brain cancer. Front Immunol. 2018, 9: 697.
[20]
B Ajami, JL Bennett, C Krieger, et al. Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool. Nat Neurosci. 2011, 14(9): 1142-1149.
[21]
PW Chen, P Bonaldo. Role of macrophage polarization in tumor angiogenesis and vessel normalization: implications for new anticancer therapies. Int Rev Cell Mol Biol. 2013, 301: 1-35.
[22]
SM Pyonteck, L Akkari, AJ Schuhmacher, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med. 2013, 19(10): 1264-1272.
[23]
NN Dong, XY Shi, SH Wang, et al. M2 macrophages mediate sorafenib resistance by secreting HGF in a feed-forward manner in hepatocellular carcinoma. Br J Cancer. 2019, 121(1): 22-33.
[24]
NA Charles, EC Holland, R Gilbertson, et al. The brain tumor microenvironment. Glia. 2012, 60(3): 502-514.
[25]
Q Lahmar, J Keirsse, D Laoui, et al. Tissue-resident versus monocyte-derived macrophages in the tumor microenvironment. Biochim Biophys Acta. 2016, 1865(1): 23-34.
[26]
Y Shi, YF Ping, WC Zhou, et al. Tumour-associated macrophages secrete pleiotrophin to promote PTPRZ1 signalling in glioblastoma stem cells for tumour growth. Nat Commun. 2017, 8: 15080.
[27]
A Nishie, M Ono, T Shono, et al. Macrophage infiltration and heme oxygenase-1 expression correlate with angiogenesis in human gliomas. Clin Cancer Res. 1999, 5(5): 1107-1113.
[28]
RA Franklin, W Liao, A Sarkar, et al. The cellular and molecular origin of tumor-associated macrophages. Science. 2014, 344(6186): 921-925.
[29]
L Bingle, NJ Brown, CE Lewis. The role of tumour- associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol. 2002, 196(3): 254-265.
[30]
FO Martinez, S Gordon. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 2014, 6: 13.
[31]
K Gabrusiewicz, A Ellert-Miklaszewska, M Lipko, et al. Characteristics of the alternative phenotype of microglia/macrophages and its modulation in experimental gliomas. PLoS One. 2011, 6(8): e23902.
[32]
T Kees, J Lohr, J Noack, et al. Microglia isolated from patients with glioma gain antitumor activities on poly (I:C) stimulation. Neuro Oncol. 2012, 14(1): 64-78.
[33]
A Mantovani, S Sozzani, M Locati, et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002, 23(11): 549-555.
[34]
A Mantovani, A Sica, S Sozzani, et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004, 25(12): 677-686.
[35]
S Müller, G Kohanbash, SJ Liu, et al. Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment. Genome Biol. 2017, 18(1): 234.
[36]
Y Komohara, K Ohnishi, J Kuratsu, et al. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J Pathol. 2008, 216(1): 15-24.
[37]
OW Yeung, CM Lo, CC Ling, et al. Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma. J Hepatol. 2015, 62(3): 607-616.
[38]
C Zhu, I Chrifi, D Mustafa, et al. CECR1-mediated cross talk between macrophages and vascular mural cells promotes neovascularization in malignant glioma. Oncogene. 2017, 36(38): 5356-5368.
[39]
L Pinton, S Magri, E Masetto, et al. Targeting of immunosuppressive myeloid cells from glioblastoma patients by modulation of size and surface charge of lipid nanocapsules. J Nanobiotechnol. 2020, 18: 31.
[40]
X Liu, F Chen, WB Li. Elevated expression of DOK3 indicates high suppressive immune cell infiltration and unfavorable prognosis of gliomas. Int Immunopharmacol. 2020, 83: 106400.
[41]
ZH Zhang, XM Huang, J Li, et al. Interleukin 10 promotes growth and invasion of glioma cells by up-regulating KPNA 2 in vitro. J Cancer Res Ther. 2019, 15(4): 927-932.
[42]
RV Lukas, C Juhász, DA Wainwright, et al. Imaging tryptophan uptake with positron emission tomography in glioblastoma patients treated with indoximod. J Neurooncol. 2019, 141(1): 111-120.
[43]
NF Brown, TJ Carter, D Ottaviani, et al. Harnessing the immune system in glioblastoma. Br J Cancer. 2018, 119(10): 1171-1181.
[44]
T Sun, YY Li, W Yang, et al. Histone deacetylase inhibition up-regulates MHC class I to facilitate cytotoxic T lymphocyte-mediated tumor cell killing in glioma cells. J Cancer. 2019, 10(23): 5638-5645.
[45]
WL Fu, WJ Wang, H Li, et al. High dimensional mass cytometry analysis reveals characteristics of the immunosuppressive microenvironment in diffuse astrocytomas. Front Oncol. 2020, 10: 78.
[46]
J Miska, C Lee-Chang, A Rashidi, et al. HIF-1α is a metabolic switch between glycolytic-driven migration and oxidative phosphorylation-driven immunosuppression of tregs in glioblastoma. Cell Rep. 2019, 27(1): 226-237.
[47]
J Wang, DY Li, HX Cang, et al. Crosstalk between cancer and immune cells: Role of tumor-associated macrophages in the tumor microenvironment. Cancer Med. 2019, 8(10): 4709-4721.
[48]
C Guruvayoorappan. Tumor versus tumor-associated macrophages: how hot is the link? Integr Cancer Ther. 2008, 7(2): 90-95.
[49]
TE Peterson, ND Kirkpatrick, YH Huang, et al. Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. Proc Natl Acad Sci USA. 2016, 113(16): 4470-4475.
[50]
R Tamura, T Tanaka, Y Akasaki, et al. The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications. Med Oncol. 2019, 37(1): 2.
[51]
CL Wang, Y Li, HL Chen, et al. Inhibition of CYP4A by a novel flavonoid FLA-16 prolongs survival and normalizes tumor vasculature in glioma. Cancer Lett. 2017, 402: 131-141.
[52]
L Zhang, YY Xu, JT Sun, et al. M2-like tumor- associated macrophages drive vasculogenic mimicry through amplification of IL-6 expression in glioma cells. Oncotarget. 2017, 8(1): 819-832.
[53]
T Hori, T Sasayama, K Tanaka, et al. Tumor- associated macrophage related interleukin-6 in cerebrospinal fluid as a prognostic marker for glioblastoma. J Clin Neurosci. 2019, 68: 281-289.
[54]
S Brandenburg, A Müller, K Turkowski, et al. Resident microglia rather than peripheral macrophages promote vascularization in brain tumors and are source of alternative pro-angiogenic factors. Acta Neuropathol. 2016, 131(3): 365-378.
[55]
C Deligne, J Hachani, S Duban-Deweer, et al. Development of a human in vitro blood-brain tumor barrier model of diffuse intrinsic pontine glioma to better understand the chemoresistance. Fluids Barriers CNS. 2020, 17(1): 37.
[56]
WZ Lin, SH Wu, XC Chen, et al. Characterization of hypoxia signature to evaluate the tumor immune microenvironment and predict prognosis in glioma groups. Front Oncol. 2020, 10: 796.
[57]
SL Shang, XR Ji, LL Zhang, et al. Macrophage ABHD5 suppresses NFκB-dependent matrix metalloproteinase expression and cancer metastasis. Cancer Res. 2019, 79(21): 5513-5526.
[58]
SL Li, J Ma, Y Si, et al. Differential expression and functions of Ehm2 transcript variants in lung adenocarcinoma. Int J Oncol. 2019, 54(5): 1747-1758.
[59]
W Zhou, XJ Yu, S Sun, et al. Increased expression of MMP-2 and MMP-9 indicates poor prognosis in glioma recurrence. Biomedecine Pharmacother. 2019, 118: 109369.
[60]
YY Liu, XY Li, YP Zhang, et al. An miR- 340-5p-macrophage feedback loop modulates the progression and tumor microenvironment of glioblastoma multiforme. Oncogene. 2019, 38(49): 7399-7415.
[61]
CV Locarno, M Simonelli, C Carenza, et al. Role of myeloid cells in the immunosuppressive microenvironment in gliomas. Immunobiology. 2020, 225(1): 151853.
[62]
S Lee, E Lee, E Ko, et al. Tumor-associated macrophages secrete CCL2 and induce the invasive phenotype of human breast epithelial cells through upregulation of ERO1-α and MMP-9. Cancer Lett. 2018, 437: 25-34.
[63]
WB Fang, M Yao, G Brummer, et al. Targeted gene silencing of CCL2 inhibits triple negative breast cancer progression by blocking cancer stem cell renewal and M2 macrophage recruitment. Oncotarget. 2016, 7(31): 49349-49367.
[64]
ZH Chen, D Hambardzumyan. Immune microenvironment in glioblastoma subtypes. Front Immunol. 2018, 9: 1004.
[65]
SW Wang, C Chen, JL Li, et al. The CXCL12/ CXCR4 Axis confers temozolomide resistance to human glioblastoma cells via up-regulation of FOXM1. J Neurol Sci. 2020, 414: 116837.
[66]
G Sokratous, S Polyzoidis, K Ashkan. Immune infiltration of tumor microenvironment following immunotherapy for glioblastoma multiforme. Hum Vaccin Immunother. 2017, 13(11): 2575-2582.
[67]
AM Stessin, MG Clausi, ZR Zhao, et al. Repolarized macrophages, induced by intermediate stereotactic dose radiotherapy and immune checkpoint blockade, contribute to long-term survival in glioma-bearing mice. J Neurooncol. 2020, 147(3): 547-555.
[68]
J Ye, YF Yang, WJ Dong, et al. Drug-free mannosylated liposomes inhibit tumor growth by promoting the polarization of tumor-associated macrophages. Int J Nanomedicine. 2019, 14: 3203-3220.
[69]
CI Chang, JC Liao, L Kuo. Macrophage arginase promotes tumor cell growth and suppresses nitric oxide-mediated tumor cytotoxicity. Cancer Res. 2001, 61(3): 1100-1106.
[70]
A Ellert-Miklaszewska, P Wisniewski, M Kijewska, et al. Tumour-processed osteopontin and lactadherin drive the protumorigenic reprogramming of microglia and glioma progression. Oncogene. 2016, 35(50): 6366-6377.
[71]
SL Shiao, AP Ganesan, HS Rugo, et al. Immune microenvironments in solid tumors: new targets for therapy. Genes Dev. 2011, 25(24): 2559-2572.
[72]
SK Biswas, A Mantovani. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010, 11(10): 889-896.
[73]
M Zhang, G Hutter, SA Kahn, et al. Anti-CD47 treatment stimulates phagocytosis of glioblastoma by M1 and M2 polarized macrophages and promotes M1 polarized macrophages in vivo. PLoS One. 2016, 11(4): e0153550.
[74]
XP Mo, ZN Zheng, Y He, et al. Antiglioma via regulating oxidative stress and remodeling tumor- associated macrophage using lactoferrin-mediated biomimetic codelivery of simvastatin/fenretinide. J Control Release. 2018, 287: 12-23.
[75]
MH Park, SY Kwon, JE Choi, et al. Intratumoral CD103-positive tumor-infiltrating lymphocytes are associated with favorable prognosis in patients with triple-negative breast cancer. Histopathology. 2020, in press, .
[76]
N Wang, HW Liang, K Zen. Molecular mechanisms that influence the macrophage m1-m2 polarization balance. Front Immunol. 2014, 5: 614.
[77]
G Natoli, S Monticelli. Macrophage activation: glancing into diversity. Immunity. 2014, 40(2): 175-177.
[78]
A Sica, A Mantovani. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012, 122(3): 787-795.
[79]
Y Degboé, B Rauwel, M Baron, et al. Polarization of rheumatoid macrophages by TNF targeting through an IL-10/STAT3 mechanism. Front Immunol. 2019, 10: 3.
[80]
L Zhang, TE Peterson, VM Lu, et al. Antitumor activity of novel pyrazole-based small molecular inhibitors of the STAT3 pathway in patient derived high grade glioma cells. PLoS One. 2019, 14(7): e0220569.
[81]
A Mantovani, G Germano, F Marchesi, et al. Cancer-promoting tumor-associated macrophages: new vistas and open questions. Eur J Immunol. 2011, 41(9): 2522-2525.
[82]
N Tajik, M Tajik, I Mack, et al. The potential effects of chlorogenic acid, the main phenolic components in coffee, on health: a comprehensive review of the literature. Eur J Nutr. 2017, 56(7): 2215-2244.
[83]
NN Xue, Q Zhou, M Ji, et al. Chlorogenic acid inhibits glioblastoma growth through repolarizating macrophage from M2 to M1 phenotype. Sci Rep. 2017, 7: 39011.
[84]
N Daftarian, S Zandi, G Piryaie, et al. Peripheral blood CD163(+) monocytes and soluble CD163 in dry and neovascular age-related macular degeneration. FASEB J. 2020, 34(6): 8001-8011.
[85]
JJ Park, SJ Hwang, JH Park, et al. Chlorogenic acid inhibits hypoxia-induced angiogenesis via down- regulation of the HIF-1α/AKT pathway. Cell Oncol. 2015, 38(2): 111-118.
[86]
G Hutter, J Theruvath, CM Graef, et al. Microglia are effector cells of CD47-SIRPα antiphagocytic axis disruption against glioblastoma. Proc Natl Acad Sci USA. 2019, 116(3): 997-1006.
[87]
F Li, B Lv, Y Liu, et al. Blocking the CD47-SIRPα axis by delivery of anti-CD47 antibody induces antitumor effects in glioma and glioma stem cells. Oncoimmunology. 2018, 7(2): e1391973.
[88]
LB Sun, HX Liang, WD Yu, et al. Increased invasive phenotype of CSF-1R expression in glioma cells via the ERK1/2 signaling pathway. Cancer Gene Ther. 2019, 26(5/6): 136-144.
[89]
KR Wiehagen, NM Girgis, DH Yamada, et al. Combination of CD40 agonism and CSF-1R blockade reconditions tumor-associated macrophages and drives potent antitumor immunity. Cancer Immunol Res. 2017, 5(12): 1109-1121.
[90]
T Hagemann, T Lawrence, I McNeish, et al. “Re-educating” tumor-associated macrophages by targeting NF-κB. J Exp Med. 2008, 205(6): 1261-1268.
[91]
KP Zeligs, MK Neuman, CM Annunziata. Molecular pathways: the balance between cancer and the immune system challenges the therapeutic specificity of targeting nuclear factor-κB signaling for cancer treatment. Clin Cancer Res. 2016, 22(17): 4302-4308.
[92]
T Barberi, A Martin, R Suresh, et al. Absence of host NF-κB p50 induces murine glioblastoma tumor regression, increases survival, and decreases T-cell induction of tumor-associated macrophage M2 polarization. Cancer Immunol Immunother. 2018, 67(10): 1491-1503.
[93]
X Cui, RT Morales, WY Qian, et al. Hacking macrophage-associated immunosuppression for regulating glioblastoma angiogenesis. Biomaterials. 2018, 161: 164-178.
[94]
WC Zhou, SQ Ke, Z Huang, et al. Periostin secreted by glioblastoma stem cells recruits M2 tumour- associated macrophages and promotes malignant growth. Nat Cell Biol. 2015, 17(2): 170-182.
[95]
G Acker, J Zollfrank, C Jelgersma, et al. The CXCR2/CXCL2 signalling pathway - An alternative therapeutic approach in high-grade glioma. Eur J Cancer. 2020, 126: 106-115.
[96]
A Tivnan, T Heilinger, EC Lavelle, et al. Advances in immunotherapy for the treatment of glioblastoma. J Neurooncol. 2017, 131(1): 1-9.
[97]
W Hugo, JM Zaretsky, L Sun, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. 2017, 168(3): 542.
[98]
S Yao, YW Zhu, GF Zhu, et al. B7-h2 is a costimulatory ligand for CD28 in human. Immunity. 2011, 34(5): 729-740.
[99]
S Chikuma. Basics of PD-1 in self-tolerance, infection, and cancer immunity. Int J Clin Oncol. 2016, 21(3): 448-455.
[100]
ME Keir, MJ Butte, GJ Freeman, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008, 26: 677-704.
[101]
FL Ricklefs, Q Alayo, H Krenzlin, et al. Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. Sci Adv. 2018, 4(3): eaar2766.
[102]
MC Speranza, C Passaro, F Ricklefs, et al. Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma. Neuro-oncology. 2018, 20(2): 225-235.
[103]
BL Dai, N Qi, JC Li, et al. Temozolomide combined with PD-1 Antibody therapy for mouse orthotopic glioma model. Biochem Biophys Res Commun. 2018, 501(4): 871-876.
[104]
B Lu, Y Zhou, ZZ Su, et al. Effect of CCL2 siRNA on proliferation and apoptosis in the U251 human glioma cell line. Mol Med Rep. 2017, 16(3): 3387-3394.
[105]
A Vakilian, H Khorramdelazad, P Heidari, et al. CCL2/CCR2 signaling pathway in glioblastoma multiforme. Neurochem Int. 2017, 103: 1-7.
[106]
JA Flores-Toro, DF Luo, A Gopinath, et al. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas. Proc Natl Acad Sci USA. 2020, 117(2): 1129-1138.
[107]
C Hanna, TA Lawrie, E Rogozińska, et al. Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis. Cochrane Database Syst Rev. 2020, 3: CD013261.
[108]
X Feng, S Liu, D Chen, et al. Rescue of cognitive function following fractionated brain irradiation in a novel preclinical glioma model. Elife. 2018, 7: e38865.
[109]
D Yan, J Kowal, L Akkari, et al. Inhibition of colony stimulating factor-1 receptor abrogates microenvironment-mediated therapeutic resistance in gliomas. Oncogene. 2017, 36(43): 6049-6058.
[110]
J Yin, KL Valin, ML Dixon, et al. The role of microglia and macrophages in CNS homeostasis, autoimmunity, and cancer. J Immunol Res. 2017, 2017: 5150678.
[111]
A Lopez, ML Cruz, G Chompre, et al. Influence of stress on the vitamin D-vitamin D receptor system, macrophages, and the local inflammatory milieu in endometriosis. Reprod Sci. 2020, in press, .
[112]
K Baidžajevas, É Hadadi, B Lee, et al. Macrophage polarisation associated with atherosclerosis differentially affects their capacity to handle lipids. Atherosclerosis. 2020, 305: 10-18.
[113]
M Maraux, A Gaillardet, A Gally, et al. Human primary neutrophil mRNA does not contaminate human resolving macrophage mRNA after efferocytosis. J Immunol Methods. 2020, 483: 112810.
[114]
KL Trout, A Holian. Multinucleated giant cell phenotype in response to stimulation. Immunobiology. 2020, 225(3): 151952.
[115]
D Gomez-Zepeda, M Taghi, JM Scherrmann, et al. ABC transporters at the blood-brain interfaces, their study models, and drug delivery implications in gliomas. Pharmaceutics. 2019, 12(1): E20.
[116]
SY Fu, M Liang, YL Wang, et al. Dual-modified novel biomimetic nanocarriers improve targeting and therapeutic efficacy in glioma. ACS Appl Mater Interfaces. 2019, 11(2): 1841-1854.
[117]
L Cui, YL Wang, M Liang, et al. Dual-modified natural high density lipoprotein particles for systemic glioma-targeting drug delivery. Drug Deliv. 2018, 25(1): 1865-1876.
Publication history
Copyright
Rights and permissions
Publication history
Received: 16 May 2020
Revised: 30 June 2020
Accepted: 04 July 2020
Published:
28 February 2021
Issue date: December 2020
Copyright
© The authors 2020
Rights and permissions
This article is published with open access at journals.sagepub.com/home/BSA
Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
FEEDBACK 
TOP